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Aims This post hoc analysis of ELIMINATE-AF evaluated requirements of unfractionated heparin (UFH) and procedure-
related bleeding in atrial fibrillation (AF) patients undergoing ablation with uninterrupted edoxaban or vitamin K an-
tagonist (VKA) therapy.
...................................................................................................................................................................................................
Methods and
results
Patients were randomized 2:1 to once-daily edoxaban 60 mg (or dose-reduced 30 mg) or dose-adjusted VKA (target
international normalized ratio: 2.0–3.0). Uninterrupted anticoagulation was mandated for 21–28 days’ pre-ablation and
90 days’ post-ablation. During ablation, UFH administration targeted an activated clotting time (ACT) of 300–400 s.
Periprocedural bleeding was differentiated between procedure-related (bleeding at puncture side, cardiac tamponade)
and unrelated events. Of 614 randomized patients, 553 received study drug and underwent catheter ablation (edoxa-
ban n = 375; VKA n = 178). The median (Q1–Q3) time from last dose to ablation procedure was 14.8 (13.3–16.5) vs.
16.5 (14.8–19.5) h (edoxaban vs. VKA group, respectively). Mean ACT (SD) >_300 s was observed in 52% edoxaban-
vs. 76% VKA-treated patients, despite a higher mean (SD) UFH dose in the edoxaban vs. VKA group [14 261 (6397)
IU vs. 11 473 (4300) IU; exploratory P-value < 0.0001]. In the edoxaban group, 13 patients (3.5%) had procedure-re-
lated bleeds of whom 9 had received an UFH dose above the median (13 000 IU). In the VKA arm, 7 patients (3.9%)
had procedure-related bleeds of whom 3 had received an UFH dose above the median (10 225 IU).
...................................................................................................................................................................................................
Conclusion The rate of procedure-related major/clinically relevant non-major bleeding did not differ between the treatment
arms despite higher doses of UFH used with edoxaban vs. VKA to achieve a target ACT during AF ablation.
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Introduction
Catheter ablation of atrial fibrillation (AF) is the most frequently per-
formed ablation procedure world-wide and constitutes an effective
treatment modality. However, the procedure can entail serious com-
plications, including stroke, transient ischaemic attack, and cardiac
tamponade.1 To minimize these complications, current guidelines
recommend continuation of oral anticoagulation with vitamin K
antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) during
the procedure, maintaining effective anticoagulation.2 Four random-
ized controlled trials compared uninterrupted VKA vs. uninterrupted
NOAC therapy in patients undergoing AF ablation.3–6 Each of these
trials demonstrated low rates of ischaemic and bleeding events in
patients treated with uninterrupted NOAC therapy. These results
have prompted the guideline recommendation to perform AF abla-
tion without interruption of warfarin or NOAC therapy.2 The guide-
lines also recommend systemic anticoagulation with unfractionated
heparin (UFH) during the ablation procedure to achieve an activated
clotting time (ACT) of >300 s to avoid procedure-related thrombo-
embolic events.1,2 Recent observations indicate that in order to
achieve this target, heparin requirements may differ in patients receiv-
ing different NOACs compared to VKA.7–11 While Calkins et al.10
demonstrated that the amount of UFH required in subjects treated
with the factor II inhibitor dabigatran or warfarin was similar, mean
UFH doses tended to be higher in patients receiving a factor Xa
inhibitor.3,5
This post hoc analysis of the ELIMINATE-AF trial evaluated the cor-
relation between UFH doses and ACT in patients undergoing AF ab-
lation on an uninterrupted edoxaban- or VKA-based anticoagulation
regimen. Particularly, the relationship between UFH doses and peri-
procedural major or clinically relevant non-major (CRNM) bleeding
events was evaluated in detail.
Methods
Study design
The design, methodology, and primary results of ELIMINATE-AF have
been previously reported in detail.6,12 In brief, ELIMINATE-AF
(ClinicalTrials.gov: NCT02942576) was a multinational, multicentre, ran-
domized, open-label, parallel-group, blinded-endpoint evaluation
(PROBE) study. The protocol was approved by the institutional review
board or independent ethics committee at each participating study cen-
tre. All patients provided written informed consent prior to enrolment.
Adult patients (>_18 years of age) with documented non-valvular AF (par-
oxysmal, <_7 days; persistent, >7 days but <_12 months; long-standing per-
sistent, >12 months) scheduled for their first or repeated catheter
ablation for AF were eligible. Patients were randomized in a 2:1 ratio to
receive edoxaban or VKA using a block randomization method. Patients
randomized to edoxaban received once-daily edoxaban 60 mg (30 mg if
they met 1 or more of the criteria for dose reduction).12 The preferred
VKA varied across countries (phenprocoumon in Germany and Belgium,
acenocoumarol in Spain, and warfarin in Belgium and in all other coun-
tries). Patients randomized to a VKA were required to maintain an inter-
national normalized ratio of 2.0–3.0 at least for the last 10 days prior to
ablation.
Uninterrupted anticoagulation was mandated for 21–28 days pre-abla-
tion and continued for 90 days post-ablation. The maximum interval be-
tween the last pre-ablation edoxaban dose and the ablation procedure
was 18 h in order to maintain sufficient inhibition of endogenous factor
Xa. During ablation, UFH was used according to contemporary guideline
recommendations1,2 targeting an ACT of 300–400 s. The first dose of
UFH was given after sheath placement before or immediately after the
transseptal puncture. For the duration of the ablation when catheters
were in the left atrium, investigators were instructed to maintain an ACT
>_300 s by administering repeated boluses of UFH. Activated clotting time
was assessed within 15 min after the administration of the bolus dose and
regularly thereafter. Study medication was restarted at least 6 h post-
sheath removal after achieving adequate haemostasis.
Parameters of coagulation were correlated with major or CRNM
bleeding events (ISTH definition). For this purpose, only those events
were considered which occurred from start of ablation up to 48 h after
the end of the ablation procedure. Periprocedural bleeding was differenti-
ated between procedure-related (bleeding at puncture side and cardiac
tamponade) and unrelated events.
Statistical analysis
The administered heparin doses and ACT values in both treatment
groups are presented descriptively. All P-values for group comparisons
are exploratory.
Results
Patient population
A total of 632 patients were enrolled at 58 sites across 11 countries
in Europe, Asia, and Canada. Of these, 614 patients were random-
ized, and 602 received at least one dose of study medication. A total
of 553 subjects (375 in the edoxaban group and 178 in the VKA
group) received study drug and underwent catheter ablation. The
baseline characteristics of the two patient groups were well balanced
(Table 1) and represented a typical AF ablation population with a
male preponderance and a mean age of 60.5 years. The median (Q1–
Q3) time interval between the last intake of study medication and
start of the ablation procedure was 14.8 (13.3–16.5) h in the edoxa-
ban group vs. 16.5 (14.8–19.5) h in the VKA group.
Heparin dosing and activated clotting
time measurements
Data on UFH use on the day of ablation were collected in 552
patients, 374 assigned to edoxaban therapy and 178 assigned to
What’s new?
• This post hoc analysis of ELIMINATE-AF showed that patients
anticoagulated with edoxaban during atrial fibrillation ablation
received a higher dose of unfractionated heparin (UFH) to
achieve recommended level of activated clotting time (ACT)
than those treated with vitamin K antagonist.
• Despite the higher UFH dose, the mean ACT was lower in
patients treated with edoxaban.
• The number of patients with procedure-related major/clinically
relevant non-major bleeding did not differ between the treat-
ment arms despite higher doses of UFH used in combination
with edoxaban.
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receive VKA. The median (Q1–Q3) UFH dose administered was
higher in the edoxaban group than in the VKA group (Table 2).
Heparin dosing tended to be lower in patients with a first ACT mea-
surement of >_300 vs. <300 s for all patients (Table 2).
The median (Q1–Q3) ACT over the course of the ablation was
lower in the edoxaban group than in the VKA group (Table 3; explor-
atory P-value <0.0001). An individual mean ACT of >_300 s over the
course of the procedure was achieved in 52% of patients in the edox-
aban group vs. 76% in the VKA group. Median (Q1–Q3) heparin dos-
ing was similar in patients with mean ACT measurement of <300 vs.
>_300 s (Table 3). In the edoxaban treatment group, the first ACT was
>_300 s for 47% and in the VKA group for 66% of patients (explor-
atory P < 0.0001; Table 4).
....................................................................................................................................................................................................................
Table 1 Patient characteristics
Total Edoxaban VKA
ITTanalysis set N 5 614 N 5 411 N 5 203
Age (years) 60.5 (53–67) 60.0 (53–67) 61.0 (52–67)
Male, n (%) 439 (71.5) 290 (70.6) 149 (73.4)
CHA2DS2-VASc score
Mean (SD) 1.7 (1.5) 1.8 (1.6) 1.7 (1.4)
Median (Q1–Q3) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–2.0)
Medical history, n (%)
Congestive heart failure 110 (17.9) 71 (17.3) 39 (19.2)
Previous CAD (prior MI, prior PCI, or prior CABG) 117 (19.2) 76 (18.6) 41 (20.3)
Previous MI 24 (3.9) 19 (4.6) 5 (2.5)
Previous stroke/TIAa 30 (4.9) 22 (5.4) 8 (3.9)
Peripheral artery disease 10 (1.6) 7 (1.7) 3 (1.5)
Diabetes mellitus 87 (14.2) 55 (13.4) 32 (15.8)
Hypertension 371 (60.4) 250 (60.8) 121 (59.6)
Mild valvular heart disease 52 (8.5) 32 (7.8) 20 (9.9)
AF type, n (%)
Paroxysmal 415 (67.6) 284 (69.1) 131 (64.5)
Persistent 166 (27.0) 105 (25.5) 61 (30.0)
Long-standing persistent 33 (5.4) 22 (5.4) 11 (5.4)
Ablation population, mITT with ablation analysis set N = 553 N = 375 N = 178
Last dose of IP to start of CA procedure (h)
Median (Q1–Q3) 15.4 (13.5–17.1) 14.8 (13.3–16.5) 16.5 (14.8–19.5)
Sheath removal to next dose of IP (h)
Median (Q1–Q3) 6.7 (6.1–8.0) 6.7 (6.1–8.0) 6.6 (6.1–7.9)
Type of CA performed, n (%)
De novo CA 460 (83.2) 315 (84.0) 145 (81.5)
Re-do CA 93 (16.8) 60 (16.0) 33 (18.5)
CA technique used, n (%)
Radiofrequency 368 (66.7) 247 (65.9) 121 (68.4)
Cryoballoon 181 (32.8) 127 (33.9) 54 (30.5)
Other 3 (0.5) 1 (0.3) 2 (1.1)
Percentage time in TTR (2.0–3.0) with VKA
N 178
Mean (SD) 64.1 (21.1)
Median 64.8
Q1–Q3 48.3–82.1
Percentage time in TTR (1.8–3.2) with VKA
N 178
Mean (SD) 80.9 (17.0)
Median 84.7
Q1–Q3 70.8–95.2
CA, catheter ablation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; IP, investigational product; ITT, intent to treat; mITT, modified intent to treat;
PCI, percutaneous coronary intention; TIA, transient ischaemic attack; TTR, time in therapeutic range; VKA, vitamin K antagonist.
aIncludes ischaemic, embolic, and undetermined; haemorrhagic stroke prohibited.
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Table 2 Heparin dose requirements in patients with ACT <300 s vs. 300 s
Heparin dose (IU) Total (N 5 553) Edoxaban (N 5 375) VKA (N 5 178)
N 552 374 178
Mean (SD) 13 361.8 (5945.3) 14 260.9 (6397.2) 11 472.6 (4300.4)
Median 12 301 13 000 10 225
Q1–Q3 10 000–16 000 10 000–17 500 8541–14 000
First ACT
<300 s
N 256 195 61
Mean (SD) 14 679.6 (6510.8) 15 423.0 (6766.6) 12 303.2 (4957.6)
Median 14 000 14 250 12 000
Q1–Q3 10 000–18 000 11 000–18 000 9000–15 500
>_300 s
N 292 176 116
Mean (SD) 12 264.4 (5136.7) 13 051.0 (5697.9) 11 070.0 (3869.7)
Median 11 000 12 500 10 000
Q1–Q3 9000–15 000 10 000–15 875 8520–13 000
Minimum ACT
<300 s
N 417 301 116
Mean (SD) 13 737.5 (6138.9) 14 515.9 (6445.5) 11 717.8 (4716.6)
Median 12 500 13 000 10 500
Q1–Q3 10 000–17 000 10 000–18 000 8400–15 000
>_300 s
N 131 70 61
Mean (SD) 12 295.1 (5113.1) 13 361.5 (6073.5) 11 071.4 (3372.7)
Median 12 000 12 500 10 250
Q1–Q3 9000–14 500 10 000–15 750 9000–13 000
Maximum ACT
<300 s
N 50 43 7
Mean (SD) 12 265.2 (5131.7) 12 889.8 (5184.4) 8428.6 (2636.7)
Median 11 000 11 720 8000
Q1–Q3 10 000–15 000 10 000–16 000 8000–9000
>_300 s
N 498 328 170
Mean (SD) 13 505.9 (6005.2) 14 482.7 (6510.2) 11 621.3 (4315.4)
Median 12 500 13 000 10 800
Q1–Q3 10 000–16 000 10 000–18 000 9000–14 000
Mean ACT
<300 s
N 219 177 42
Mean (SD) 13 833.8 (6432.1) 14 427.3 (6689.9) 11 332.7 (4463.9)
Median 12 500 13 000 10 000
Q1–Q3 10 000–16 331 10 000–17 000 8000–13 000
>_300 s
N 329 194 135
Mean (SD) 13 099.0 (5574.7) 14 180.1 (6108.6) 11 545.5 (4266.4)
Median 12 000 13 000 10 600
Q1–Q3 10 000–16 000 10 000–17 500 9000–14 000
ACT, activated clotting time; IU, international units; SD, standard deviation.
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Periprocedural anticoagulation and
bleeding events
Between sheath insertion and up to 48 h after sheath removal, major,
or CRNM bleeding events occurred in 17 (4.5%) edoxaban- com-
pared with 7 (3.9%) VKA-treated patients (Table 5). In the edoxaban
group, 11 of the 17 patients (65%) with bleeding events had received
an UFH dose above the median (13 000 IU) while in the VKA arm, 3
of 7 patients (43%) with bleeding events had received an UFH dose
above the median (10 225 IU) (Table 5). Procedure-related (bleeding
at puncture site and cardiac tamponade) major or CRNM bleeding
events occurred in 13 (3.5%) edoxaban- vs. 7 (3.9%) VKA-treated
patients (Table 6). In the edoxaban group, 9 of 13 patients with proce-
dure-related bleeds had received an UFH dose above the median
(13 000 IU) while in the VKA arm, 3 of 7 patients with procedure-re-
lated bleedings received an UFH dose above the median (10 225 IU)
(Figure 1).
Discussion
The present post hoc analysis of the ELIMINATE-AF trial shows that
patients assigned to edoxaban during AF ablation procedure received
a higher dose of UFH than those treated with VKA. Despite the
higher administered UFH dose, the mean ACT was lower in the
group of subjects treated with edoxaban. The number of patients
with major or CRNM bleeding events related to the ablation proce-
dure did not differ between the treatment arms despite higher doses
of UFH used in combination with edoxaban. Of note, in the edoxa-
ban group, 9 of 13 major or CRNM bleeding events occurred in
patients who received an UFH dose above the median.
Our observations confirm those reported from other studies using
uninterrupted factor Xa therapy around the time of AF ablation and
extend these findings specifically to patients anticoagulated with
edoxaban. For instance, in the VENTURE-AF study, the average total
heparin dose used to manage ACT in patients undergoing catheter
....................................................................................................................................................................................................................
Table 3 Overview of ACT
Total (N 5 553) Edoxaban (N 5 375) VKA (N 5 178)
Individual mean ACT (s)
N 548 371 177
Mean (SD) 314.2 (51.4) 302.8 (41.6) 338.0 (61.2)
Median 307.7 301.4 332.6
Q1–Q3 281.6–341.5 277.0–330.4 300.5–371.0
Mean ACT categories, n (%)
<300 s 219 (40.0) 177 (47.7) 42 (23.7)
>_300 s 329 (60.0) 194 (52.3) 135 (76.3)
Individual first ACT (s)
N 548 371 177
Mean (SD) 307.3 (89.5) 293.9 (76.7) 335.2 (106.7)
Median 304.0 293.0 348.0
Q1–Q3 250.0–365.0 246.0–350.0 256.0–400.0
First ACT categories, n (%)
<300 s 256 (46.7) 195 (52.6) 61 (34.5)
>_300 s 292 (53.3) 176 (47.4) 116 (65.5)
Individual minimum ACT (s)
N 548 371 177
Mean (SD) 246.3 (75.8) 240.3 (65.3) 258.8 (93.0)
Median 240.0 240.0 246.0
Q1–Q3 182.0–296.5 187.0–284.0 179.0–320.0
Minimum ACT categories, n (%)
<300 s 417 (76.1) 301 (81.1) 116 (65.5)
>_300 s 131 (23.9) 70 (18.9) 61 (34.5)
Individual maximum ACT (s)
N 548 371 177
Mean (SD) 365.8 (65.2) 350.7 (53.7) 397.5 (75.2)
Median 361.0 351.0 390.0
Q1–Q3 328.5–395.0 317.0–376.0 357.0–426.0
Maximum ACT categories, n (%)
<300 s 50 (9.1) 43 (11.6) 7 (4.0)
>_300 s 498 (90.9) 328 (88.4) 170 (96.0)
ACT, activated clotting time; SD, standard deviation.
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ablation for AF was higher in patients receiving rivaroxaban vs. those
receiving VKA (13.871 vs. 10.964 units; P < 0.001).3 Similarly, a larger
dose of UFH was required with uninterrupted apixaban compared
with VKA to achieve the target ACT >_300 s, and the ACT during the
procedure was lower (342.1± 23.1 vs. 363 ± 26.5 s, P < 0.001) with
apixaban.13 The comparable observation was made in the AXAFA-
AFNET 5 trial.5 In contrast, a sub-analysis of the RE-CIRCUIT trial
has recently shown that a similar amount of UFH was needed in
patients anticoagulated with dabigatran vs. those treated with warfa-
rin to achieve an ACT of >300 s during ablation.10 These studies,
however, did not report on bleeding events in relation to UFH dose
or ACT.
..........................................................................................................................................................
....................................................................................................................................................................................................................
..................................................................................................................................................................................
....................................................................................................................................................................................................................
Table 4 ACTand heparin dose according to the time from the last dose of study medication edoxaban/VKA to start
of the ablation procedure (for sheath insertion and trans-septal puncture)
CA procedure performed, n (%) Time from edoxaban dose to septal puncture (N 5 375, 100%)
0 to <8 h 8 to <16 h 16 to <24 h 24 h Total
N (%) 3 (0.8) 248 (66.1) 118 (31.5) 6 (1.6) 375 (100.0)
Heparin dose (IU)
N 3 248 117 6 374
Mean (SD) 14 300.0 (2696.3) 14 280.8 (6428.4) 14 262.4 (6477.0) 13 388.8 (5865.7) 14 260.9 (6397.2)
Median 13 000.0 13 000.0 12 500.0 12 750.0 13 000.0
Q1–Q3 12 500.0–17 400.0 10 000.0–17 750.0 10 000.0–17 000.0 8000.0–19 000.0 10 000.0–17 500.0
First ACT, n (%)
0 to <100 s 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
100 to <200 s 0 (0.0) 32 (12.9) 7 (6.1) 1 (20.0) 40 (10.8)
200 to <300 s 0 (0.0) 104 (41.9) 49 (42.6) 2 (40.0) 155 (41.8)
>_300 s 3 (100.0) 112 (45.2) 59 (51.30) 2 (40.0) 176 (47.4)
Total 3 (100.0) 248 (100.0) 115 (100.0) 5 (100.0) 371 (100.0)
Mean ACT, n (%)
0 to <100 s 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
100 to <200 s 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
200 to <300 s 1 (33.3) 127 (51.2) 46 (40.0) 3 (60.0) 177 (47.7)
>_300 s 2 (66.7) 121 (48.8) 69 (60.0) 2 (40.0) 194 (52.3)
Total 3 (100.0) 248 (100.0) 115 (100.0) 5 (100.0) 371 (100.0)
Time from VKA dose to septal puncture (N 5 178, 100%)
0 to <8 h 8 to <16 h 16 to <24 h 24 h Total
N (%) 2 (1.1) 77 (43.3) 70 (39.3) 29 (16.3) 178 (100.0)
Heparin dose (IU)
N 2 77 70 29 178
Mean (SD) 11 197.5 (5377.6) 11 000.5 (4468.9) 10 767.6 (3517.2) 14 446.6 (4490.0) 11 472.6 (4300.4)
Median 11 197.5 10 000.0 10 000.0 14 000.0 10 225.0
Q1–Q3 7395.0–15 000.0 8000.0–12 500.0 8500.0–12 500.0 12 000.0–16 000.0 8541.0–14 000.0
First ACT, n (%)
0 to <100 s 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
100 to <200 s 0 (0.0) 13 (16.9) 7 (10.0) 4 (14.3) 24 (13.6)
200 to <300 s 0 (0.0) 13 (16.9) 15 (21.4) 9 (32.1) 37 (20.9)
>_300 s 2 (100.0) 51 (66.2) 48 (68.6) 15 (53.6) 116 (65.5)
Total 2 (100.0) 77 (100.0) 70 (100.0) 28 (100.0) 177 (100.0)
Mean ACT, n (%)
0 to <100 s 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
100 to <200 s 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 1 (0.5)
200 to <300 s 0 (0.0) 18 (23.4) 14 (20.0) 9 (32.1) 41 (23.2)
>_300 s 2 (100.0) 58 (75.3) 56 (80.0) 19 (67.9) 135 (76.3)
Total 2 (100.0) 77 (100.0) 70 (100.0) 28 (100.0) 177 (100.0)
ACT, activated clotting time; IU, international units; SD, standard deviation; VKA, vitamin K antagonist.
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The reason for this difference in UFH requirements in patients’
anticoagulated with different NOACs is not entirely clear.11 A likely
explanation could be that dabigatran, as a direct thrombin inhibitor,
can prolong activated partial thromboplastin time (aPTT) and ACT in
a dose-dependent manner, similar to VKAs.14 Factor Xa inhibitors,
on the other hand, may affect ACT or aPTT to a lesser degree.11 Our
observations are in line with other reports which also found shorter
baseline ACT in patients on edoxaban therapy.15 This suggests that
patients treated with edoxaban, rivaroxaban, or apixaban are
expected to need higher doses of UFH to maintain ACT. It has there-
fore been speculated that use of ACT to reflect global intraproce-
dural anticoagulation is limited in the presence of uninterrupted
NOAC therapy, particularly when using factor Xa inhibitors.11
In almost all patients in the edoxaban arm, the time interval be-
tween the last edoxaban dose to septal puncture was <24 h, hence
anticoagulation was truly uninterrupted (Table 4). The findings from
this analysis attest to the safety of an uninterrupted NOAC strategy
in patients undergoing AF ablation. Specifically, the low incidence of
major or CRNM bleeding endpoints in the edoxaban group despite
higher doses of UFH used, is reassuring.
The present analysis has some limitations. Among those is the rela-
tively small sample size, residual bias due to the non-blinded nature
of the study, and other inherent inadequacies of post hoc analyses. In
addition, it is important to emphasize that the occurrence of vascular
access bleeding after the ablation procedure may not depend only on
anticoagulation drugs but also on multiple other factors such as the
mode of puncture (e.g. ultrasound-guided vs. landmark-guided),
sheath management after the procedure (e.g. immediate removal
with Z stitch vs. delayed removal with compression) or the use of
protamine.
Figure 1 Procedure- and non-procedure-related major or
CRNM bleeding events (ISTH) occurring from start of ablation up
to 48 h after the end of the ablation procedure. CRNM, clinically rel-
evant non-major; ISTH, International Society on Thrombosis and
Haemostasis; VKA, vitamin K antagonist.
....................................................................................................................................................................................................................
Table 5 Major or CRNM bleeding events (ISTH) occurring from start of ablation up to 48 h after the end of the abla-
tion procedure
Total (N 5 553), n (%) Edoxaban (N 5 375), n (%) VKA (N 5 178), n (%)
Major or CRNM bleeding (ISTH) 24 (4.3) 17 (4.5) 7 (3.9)
Heparin dose < median of treatment arma 6 4
Heparin dose >_ median of treatment arma 11 3
Major bleeding (ISTH) 10 (1.8) 7 (1.9) 3 (1.7)
Heparin dose < median of treatment arma 2 1
Heparin dose >_ median of treatment arma 5 2
CRNM, clinically relevant non-major bleeding; ISTH, International Society on Thrombosis and Haemostasis.
aMedian heparin dose was 13 000 IU in edoxaban arm and 10 225 IU in VKA arm.
....................................................................................................................................................................................................................
Table 6 Procedure-related major or CRNM bleeding events (ISTH) occurring from start of ablation up to 48 h after
the end of the ablation procedure
Total (N 5 553), n (%) Edoxaban (N 5 375), n (%) VKA (N 5 178), n (%)
Major or CRNM bleeding (ISTH) 20 (3.6) 13 (3.5) 7 (3.9)
Heparin dose < median of treatment arma 4 4
Heparin dose >_ median of treatment arma 9 3
Major bleeding (ISTH) 9 (1.6) 6 (1.6) 3 (1.7)
Heparin dose < median of treatment arma 1 1
Heparin dose >_ median of treatment arma 5 2
CRNM, clinically relevant non-major bleeding; ISTH, International Society on Thrombosis and Haemostasis; IU, international units.
aMedian heparin dose was 13 000 IU in edoxaban arm and 10 225 IU in VKA arm.
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Conclusions
The present analysis of the ELIMINATE-AF trial shows that consider-
ably higher doses of UFH were needed with edoxaban vs. VKA to
achieve a target ACT during AF ablation. Nevertheless, the number
of patients with major or CRNM bleeding events related to the abla-
tion procedure did not differ between treatments despite higher
doses of UFH used in combination with edoxaban. However, in the
edoxaban group, 9/13 major or CRNM bleeding events occurred in
patients who received an UFH dose above the median. Careful post-
operative surveillance appears to be indicated in patients in whom
higher UFH doses had been administered during ablation.
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